Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 27 Neoplasm Metastasis 9 Stomach Neoplasms 7 Ovarian Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Esophageal Neoplasms 3 Endometrial Neoplasms 3 Sarcoma 2 Salivary Gland Neoplasms 2 Recurrence 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Melanoma 2 HER2-positive Gastric Cancer 2 Carcinoma, Renal Cell 2 Brain Neoplasms 2 Advanced Solid Tumor 2 Advanced Breast Cancer 2 Adenocarcinoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Unresectable Locally Recurrent Breast Cancer 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Testicular Neoplasms 1

Interventions

trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 liposomal doxorubicin 1 eribulin 1 Vinorelbine 1 Paclitaxel 1 Gemcitabine 1 Epirubicin 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HER2-negative Breast Cancer × trastuzumab deruxtecan × Clear all

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡